Testing darolutamide for salivary gland cancers driven by testosterone
Official title: A Phase 2 Study of Darolutamide in Combination With Leuprolide Acetate in Hormone-Therapy Naive Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer
Run by National Cancer Institute (NCI) · NCT05669664 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing if a new combination of medications can help people with certain types of salivary gland cancers that are hard to treat.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 21 (estimated) |
| Sponsor | National Cancer Institute (NCI) NIH |
| Locations | 27 sites (Irvine, California and 26 other locations) |
| Trial ID | NCT05669664 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with confirmed androgen receptor positive salivary gland cancer that is recurrent, metastatic, or unresectable.
✕Probably not a fit
Patients who have previously received androgen receptor-targeted therapy or those with a performance status greater than 2 may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This phase II trial evaluates the effectiveness of darolutamide, an androgen receptor inhibitor, in combination with leuprolide acetate, a gonadotropin-releasing hormone agonist, for treating patients with androgen receptor positive salivary gland cancers that are recurrent, metastatic, or unresectable. The study aims to assess the best overall response rate, progression-free survival, and overall survival of participants over one year. Patients will receive darolutamide orally and leuprolide acetate via injection, with regular monitoring through biopsies and imaging. The trial also explores molecular and genomic biomarkers to understand treatment responses better.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with aggressive salivary gland cancers that currently have limited treatment options.
How similar studies have gone: While this approach is novel for salivary gland cancers, similar strategies using androgen receptor inhibitors have shown promise in other cancer types.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients must have histologically or cytologically confirmed salivary gland cancer that is recurrent/metastatic or unresectable/locally advanced, with AR expression detected by immunohistochemistry (IHC) on a Clinical Laboratory Improvement Act (CLIA)-approved assay. Androgen receptor testing by immunohistochemistry (IHC) can be performed locally in a CLIA (Clinical Laboratory Improvement Amendments) certified lab * Patients must have measurable disease * Patients must have not had prior AR-targeted therapy, except for AR-targeted therapy administered in the neoadjuvant and/or adjuvant setting and with disease recurrence more than 6 months since treatment completion * Age \>= 18 years. Because no dosing or adverse event data are currently available on the use of darolutamide in combination with leuprolide acetate in patients \< 18 years of age, children are excluded from this study * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 (Karnofsky \>= 60%) * Absolute neutrophil count \>= 1,000/mcL * Platelets \>= 100,000/mcL * Total bilirubin =\< 1.5 x institutional upper limit of normal (ULN) (exception: patients with elevated bilirubin due to Gilbert's disease would be eligible for the trial) * Aspartate aminotransferase (AST) (serum (glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase (\[SGPT\]) =\< 3 x institutional ULN * Creatinine =\< 1.5 x institutional ULN * Glomerular filtration rate (GFR) \>= 30 mL/min/1.73 m\^2 (by Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\]) * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load * Patients with treated brain metastases are eligible * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better * The effects of darolutamide on the developing human fetus are unknown. For this reason and because androgen receptor inhibitor agents as well as other therapeutic agents used in this trial are known to be teratogenic (leuprolide-acetate), women of child-bearing potential and men must agree to use adequate contraception (non-hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men and women treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 7 days after completion of darolutamide administration or after the depot interval for the leuprolide-acetate dose used has been completed, whichever is longer * Ability to understand and the willingness to sign a written informed consent document * Patients must have tumors that are safely accessible for biopsy. * Note: Two research biopsies are mandated in this trial. If the biopsy is deemed to be unsafe after attempting the first biopsy, the patient will remain eligible for the trial and subsequent tumor biopsies will not be required Exclusion Criteria: * Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> grade 1) with the exception of alopecia and peripheral neuropathy * Patients with a vascular or ischemic event within 6 months of study registration * Patients who are receiving any other investigational agents * History of allergic reactions attributed to compounds of similar chemical or biologic composition to darolutamide or leuprolide acetate * Patients on combined P-gp and strong or moderate CYP3A inducers or BCRP substrates are excluded. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product * Patients with uncontrolled intercurrent illness * Pregnant women are excluded from this study because darolutamide is an androgen receptor inhibitor agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with darolutamide and leuprolide-acetate, breastfeeding should be discontinued if the mother is treated with darolutamide and leuprolide-acetate. These potential risks may also apply to other agents used in this study. * Patients with moderate hepatic impairment (Child-Pugh Class B or C)
Where it's running
-
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California, United States Recruiting -
Los Angeles General Medical Center
Los Angeles, California, United States Recruiting -
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States Recruiting -
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, United States Recruiting -
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States Recruiting -
UCHealth University of Colorado Hospital
Aurora, Colorado, United States Recruiting
Show 21 more locations
-
Emory University Hospital Midtown
Atlanta, Georgia, United States Recruiting -
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States Recruiting -
UC Comprehensive Cancer Center at Silver Cross
New Lenox, Illinois, United States Recruiting -
University of Chicago Medicine-Orland Park
Orland Park, Illinois, United States Recruiting -
UChicago Medicine Northwest Indiana
Crown Point, Indiana, United States Recruiting -
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, United States Recruiting -
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States Recruiting -
Memorial Sloan Kettering Bergen
Montvale, New Jersey, United States Recruiting -
Memorial Sloan Kettering Commack
Commack, New York, United States Recruiting -
Memorial Sloan Kettering Westchester
Harrison, New York, United States Recruiting -
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, United States Recruiting -
Memorial Sloan Kettering Cancer Center
New York, New York, United States Recruiting -
Memorial Sloan Kettering Nassau
Uniondale, New York, United States Recruiting -
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States Recruiting -
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States Recruiting -
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, United States Recruiting -
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, United States Recruiting -
University of Virginia Cancer Center
Charlottesville, Virginia, United States Recruiting -
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison, Wisconsin, United States Recruiting -
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, United States Recruiting -
M D Anderson Cancer Center
Houston, Texas, United States Suspended
Study contacts
- Principal investigator: Alan L Ho — JHU Sidney Kimmel Comprehensive Cancer Center LAO
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparing treatments for advanced HER2-positive salivary gland cancer
This study is testing if a new drug called T-DM1 works better than the usual treatment for people with advanced HER2-positive salivary gland cancer, while also looking at another drug for those with lower levels of HER2.
-
Registry for postoperative radiochemotherapy in salivary gland cancer
This study is testing a new combined treatment of radiation and chemotherapy after surgery for people with advanced salivary gland cancer to see how well it works and how patients tolerate it.
-
Evaluating Ivonescimab for advanced salivary gland cancers
This study is testing a new treatment called Ivonescimab to see if it can help people with advanced salivary gland cancers feel better and improve their health.
-
Multi-omics analysis of progression and tumor biology in head and neck adenoid cystic carcinoma
We will test whether different tumor biology types in people with metastatic head and neck adenoid cystic carcinoma explain why some cancers grow slowly while others grow faster.
-
Implantable microdevice drug screening for salivary and head and neck cancers
This will test whether a tiny implantable microdevice can safely and quickly deliver and screen multiple cancer drugs inside salivary gland and other head and neck tumors in patients scheduled for surgical removal.
-
Abiraterone with dalpiciclib in AR-positive, HER-2 negative salivary gland cancer
This phase 2 trial tests whether combining abiraterone and dalpiciclib helps people with AR-positive, HER-2 negative salivary gland cancer that has come back or spread.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.